Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00890448 · ClinicalTrials.gov registry record
Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate
A clinical trial of Toxicity, sponsored by Takeda.
- Completed
- Registry status
- 66
- Enrollment target
- 19
- Study locations
NCT00890448 is a study of Toxicity that has completed, run by Takeda. The registered enrollment target is 66 participants. The trial reports 19 study locations across 5 states.
The verdict
NCT00890448, a study of Toxicity, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- 66 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of this study is to examine the genetic contribution to the mechanism of lapaquistat acetate- induced hepatic abnormalities.
Conditions Studied
Interventions
- OTHER Pharmacogenomic whole blood sampling
Study Locations (19)
Other
- - Córdoba
- - Québec
- - Sainte-Foy
- - Santiago
- - Havírov-Šumbark
- - Oulu
- - Nuremberg
- - Riga
- - Groningen
- - Gdansk
- - Moscow
- - Saratov
- - Žilina
- - Johannesburg
Florida
- - Jacksonville
- - Jupiter
Idaho
- - Idaho Falls
Virginia
- - Richmond
Scotland
- - Glasgow
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00890448
The ClinicalTrials.gov registry entry for NCT00890448 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Toxicity appearing as the primary indexed condition, and to 1 intervention - of which Pharmacogenomic whole blood sampling is the first listed.
NCT00890448 reports 19 study locations spanning 5 distinct geographic areas - top geographies include Other, Florida, Idaho.
Frequently Asked Questions
What is clinical trial NCT00890448 about?
NCT00890448 is a clinical study titled "Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate". The purpose of this study is to examine the genetic contribution to the mechanism of lapaquistat acetate- induced hepatic abnormalities.
What is the current status of trial NCT00890448?
This trial is currently completed. The enrollment target is 66 participants. The study started on 2009-05. Estimated completion is 2010-05.
What conditions does trial NCT00890448 study?
This clinical trial studies the following conditions: Toxicity.
What interventions are being tested in trial NCT00890448?
The interventions under investigation include: Pharmacogenomic whole blood sampling (OTHER).
Who is sponsoring clinical trial NCT00890448?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00890448 being conducted?
This trial has 19 study locations across Florida, Idaho, Virginia, Scotland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Toxicity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.